Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron Variant of Concern

3

Fulvia Mazzaferri¹, Massimo Mirandola¹, Alessia Savoldi¹, Pasquale De Nardo¹, Matteo Morra¹, Maela
Tebon¹, Maddalena Armellini¹, Giulia De Luca¹, Lucrezia Calandrino², Lolita Sasset², Denise D'Elia³,
Emanuela Sozio³, Elisa Danese⁴, Davide Gibellini⁵, Isabella Monne⁶, Giovanna Scroccaro⁷, Nicola Magrini⁸,
Annamaria Cattelan², Carlo Tascini³, MANTICO Working Group, and Evelina Tacconelli¹

8

MANTICO working group: Francesca Simbeni¹, Alessandro Castelli¹, Ilaria Dalla Vecchia¹, Chiara Konishi
de Toffoli¹, Gaia Maccarrone¹, Marco Meroi¹, Chiara Perlini¹, Matilde Rocchi¹, Giulia Rosini¹, Laura Rovigo¹,
Lorenzo Tavernaro¹, Amina Zaffagnini¹, Ilaria Currò¹, Ruth Joanna Davis¹, Elena Agostini², Carla Benfatto²,
Nicola Bonadiman², Marco Canova², Giuseppe Lombardo², Daniele Mengato², Danilo Puntrello², Francesca
Prataviera³, Tosca Semenzin³, Dario Carloni³, Giuseppe Lippi⁴, Davide Negrini⁴, Martina Montagnana⁴,
Riccardo Cecchetto⁵, Alice Fusaro⁶, Francesco Bonfante⁶, Elisa Palumbo⁶, Edoardo Giussani⁶

16 ¹ Infectious Diseases Division, Department of Diagnostics and Public Health, University of Verona, Verona, Italy: ² Infectious Disease Unit, Padova University Hospital, Padua, Italy; ³Infectious Diseases Division, 17 18 Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy; 19 ⁴ Section of Clinical Biochemistry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy; ⁵ Microbiology and Virology Unit, Department of Diagnostics and Public Health, 20 University of Verona, Verona, Italy; ⁶ Viral genomics and transcriptomics Laboratory, Istituto Zooprofilattico 21 Sperimentale delle Venezie, Legnaro, Italy; ⁷ Direzione Farmaceutico, Protesica, Dispositivi Medici, Regione 22 23 del Veneto, Venice, Italy; ⁸ Italian Medicines Agency, Rome, Italy

24

25 Corresponding author

26 Evelina Tacconelli

- 27 Infectious Diseases Division, Department of Diagnostics and Public Health, University of Verona
- 28 Piazzale Scuro 10, 37134, Verona, Italy
- 29 evelina.tacconelli@univr.it

30 Background

Recent in-vitro data have shown that the activity of monoclonal antibodies (mAbs) targeting SARS-CoV-2 varies according to the Variant of Concern (VOC). No studies have compared the clinical efficacy of different mAbs against Omicron VOC.

34 Methods

35 The MANTICO trial is a non-inferiority randomised controlled trial comparing the clinical efficacy of 36 bamlanivimab/etesevimab, casirivimab/imdevimab, and sotrovimab in outpatients aged 50 or older with early 37 COVID-19. As the patient enrolment was interrupted for possible futility after the onset of the Omicron wave, 38 the analysis was performed according to the SARS-CoV-2 VOC. The primary outcome was COVID-19 39 progression (hospitalisation, need of supplemental oxygen therapy, or death through day 14). Secondary 40 outcomes included the time to symptom resolution, assessed using the product-limit method. Kaplan-Meier 41 estimator and Cox proportional hazard model were used to assess the association with predictors. Log rank 42 test was used to compare survival functions.

43 Results

Overall, 319 patients were included. Among 141 patients infected with Delta, no disease progression was recorded and the time to symptom resolution did not differ significantly between treatment groups (Log-rank Chi-square 0.22, *p* 0.895). Among 170 patients infected with Omicron (80.6% BA.1, 19.4% BA.1.1), two disease progressions were recorded in the bamlanivimab/etesevimab group and the median time to symptom resolution was 5 days shorter in the sotrovimab group compared to bamlanivimab/etesevimab and casirivimab/imdevimab (HR 0.526 and HR 0.451, 95% CI 0.359 - 0.77 and 95% CI 0.303 - 0.669, *p* 0.001 and 0.0001, respectively).

51 Conclusions

These results confirm the in-vitro data of superiority of sotrovimab versus casirivimab/imdevimab and bamlanivimab/etesivamab in reducing the time to recovery in patients infected with Omicron BA.1 and BA.1.1, while no difference was detected in Delta infections. Casirivimab/imdevimab seems to maintain a role in preventing severe COVID-19 in the Omicron population. Adaptive clinical trials comparing mAbs by VOC should be pursued to promptly inform clinical recommendations.

57

58 Funding

59 This trial was funded by the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA). The VOC 60 identification was funded by the ORCHESTRA (Connecting European Cohorts to Increase Common and

- 61 Effective Response to SARS-CoV-2 Pandemic) project, which has received funding from the European
- 62 Union's Horizon 2020 research and innovation programme under grant agreement No 101016167.
- 63
- 64 Clinical trial number
- 65 NCT05205759

66 Introduction

67 Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 68 (SARS-CoV-2), has spread globally and poses a major challenge to healthcare systems worldwide. A high 69 incidence of hospitalisation and death due to COVID-19 has been reported among older patients and those 70 with certain coexisting conditions, such as obesity, diabetes mellitus, cardiovascular disease, chronic 71 obstructive pulmonary disease, and chronic kidney disease [1, 2]. The implementation of mass vaccination 72 campaigns has markedly reduced the healthcare burden related to COVID-19. Nevertheless, SARS-CoV-2 73 vaccination rates differ considerably across countries and growing evidence suggests a reduced efficacy of 74 vaccines against new viral Variants of Concern (VOC) [3-6].

75 Therapeutic agents directed against SARS-CoV-2 have been developed to prevent the disease progression. 76 especially addressing high-risk groups of patients. Neutralizing monoclonal antibodies (mAbs) target the 77 spike protein of SARS-CoV-2 that mediates viral entry into host cells [7]. Based on the results of randomised 78 placebo-controlled trials showing the efficacy in preventing COVID-19 progression, drug regulatory 79 authorities, such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), 80 and the Italian Medicines Agency (AIFA), had granted the emergency use authorization status for 81 bamlanivimab 700 mg combined with etesevimab 1400 mg, casirivimab 600 mg combined with imdevimab 82 600 mg, and sotrovimab 500 mg to treat early COVID-19 in patients at high risk of progression [8-10]. To 83 date, no randomised trials have compared the efficacy of these mAbs in preventing severe COVID-19.

This paper reports the results of the MANTICO trial, a non-inferiority randomised controlled trial comparing the clinical efficacy of routinely-used mAbs in a real-life setting of outpatients aged 50 or older with early mild-to-moderate COVID-19. The patient enrolment started in December 2021 and was interrupted after the publication of in-vitro evidence that two treatments under investigation (bamlanivimab/etesevimab and casirivimab/imdevimab) were not effective against the new emerging viral Omicron VOC [3-5]. The analysis is therefore restricted to 319 randomised patients, who were enrolled up to the interruption for possible futility, and was performed according to the SARS-CoV-2 VOC (Delta and Omicron).

91 Methods

92 Trial design

93 The trial was designed as a pragmatic, randomised, single-blind, non-inferiority, parallel group, multi-centre, 94 controlled trial. Eligible subjects were outpatients aged 50 years or older, presenting with a positive test 95 (either direct antigen or nucleic acid SARS-CoV-2) and mild to moderate COVID-19 symptoms within 4 days 96 of the onset [11]. COVID-19 symptoms included cough, nasal congestion, sore throat, feeling hot or feverish, 97 myalgia, fatigue, headache, anosmia/ageusia, nausea, vomiting, and/or diarrhoea [12]. Predefined exclusion 98 criteria included a peripheral oxygen saturation level of 93% or less on room air, a respiratory rate of 30 or 99 more breaths per minute, a heart rate of 125 or more beats per minute, and previous COVID-19 treatments 100 with mAbs.

Participants were randomly assigned in a 1:1:1 ratio to receive a single intravenous infusion over a period of 102 1 hour, consisting of a combination of 700 mg of bamlanivimab and 1400 mg of etesevimab or 500 mg of 103 sotrovimab or a combination of 600 mg of casirivimab and 600 mg of imdevimab. The study drugs were 104 diluted to 250 mL with normal saline. Patients were masked to treatment group assignment. Randomisation 105 was computer-generated in permuted blocks with a stratification based on site. The allocated drug was 106 revealed to the investigator using an online randomisation module within the REDCap data management 107 system [13].

The trial was conducted in accordance with the principles of the Declaration of Helsinki, the international ethical guidelines of the Council for International Organizations of Medical Sciences, the International Council for Harmonisation Good Clinical Practice guidelines, and applicable laws and regulations. All patients or their legally authorized representatives provided written informed consent. This study is registered with ClinicalTrials.gov, NCT05205759, where details on the sample size determination are provided.

114 Outcomes

The composite primary outcome was the COVID-19 progression, defined as hospitalisation, need of supplemental oxygen therapy, or death from any cause through day 14. The presence of any of the three variables qualified the presence of the COVID-19 progression. Prespecified secondary outcomes were emergency department visits through day 28, all-cause mortality through day 28, duration of supplemental oxygen therapy, rate and duration of non-invasive ventilation and mechanical ventilation, and time to sustained patient-reported symptom resolution, which was defined as the absence of any symptom related to COVID-19 for at least 24 hours [14].

122 Predictors

123 The main predictor was the treatment regimen randomised at enrolment (bamlanivimab/etesevimab, 124 casirivimab/imdevimab, and sotrovimab). All patients were assessed at baseline for the following predictors 125 to be tested for association with the time to symptom resolution: age, sex, body mass index, relevant 126 comorbidities (diabetes for which medication was warranted, cardiovascular disease [hypertension, coronary 127 artery disease, congestive heart failure], chronic kidney disease, chronic liver disease, chronic pulmonary 128 disease, active cancer, transplant, and other immunocompromising conditions), SARS-CoV-2 serological 129 status (anti-spike IgG), and SARS-CoV-2 vaccination status. The SARS-CoV-2 serological status was 130 categorized as serum antibody-negative (if test results were negative), serum antibody-positive (if test results 131 were positive), or other (inconclusive or unknown results). The SARS-CoV-2 vaccination status was 132 categorised as not vaccinated, partial or complete primary COVID-19 vaccination series administered more 133 than 180 days before the enrolment, complete primary COVID-19 vaccination series administered 180 days 134 or less before the enrolment, and booster vaccination [6]. These categories were further collapsed as not 135 vaccinated and partial or complete primary COVID-19 vaccination series administered more than 180 days 136 before the enrolment versus complete primary COVID-19 vaccination series administered 180 days or less 137 before the enrolment and booster vaccination.

138 Procedures and tools

Outpatient visits were scheduled at baseline, 14±3 days and 30±3 days after the randomisation. Patients were considered lost to follow-up if they repeatedly did not participate in scheduled visits and could not be contacted by the investigators. Medical evaluation, vital signs recording, and laboratory tests were performed at each visit. If patients missed the visits, they were called by telephone to assess clinical conditions.

The SARS-CoV-2 serological status was assessed using LIAISON SARS-CoV-2 TrimericS IgG assay (DiaSorin), an indirect chemiluminescence immunoassay (CLIA) detecting IgG against the spike viral protein in its native trimeric conformation, which includes receptor-binding domain and N-terminal domain sites from the three subunit S1. According to the to manufacturer's instructions, Binding Antibody Units (BAU)/mL \geq 33.8 were considered positive for anti-trimeric spike protein specific IgG antibodies.

Nasopharyngeal swabs were processed using MagMAX Viral/Pathogen Nucleic Acid Isolation Kit and KingFisher automated extraction system (ThermoFisher Scientific). Viral RNA was detected using COVIDSeq amplicon-based Next Generation Sequencing Test combined with COVIDSeq V4 Primer Pool (Illumina, Inc.). Sequencing libraries were synthesized using automated Microlab STAR liquid handler (Hamilton Company). Pooled samples were quantified using Qubit 2.0 fluorometer (Invitrogen Inc.). Next

generation sequencing was performed in 150 PE mode on NextSeq 550 Sequencing System (Illumina, Inc.)
or MiSeq System (Illumina, Inc.) using the NextSeq 500/550 Mid Output Kit v2.5 or the Miseq Reagent Kit
v3, respectively.

156 Statistical analysis

157 For continuous variables, mean and standard deviation or median and IQR were calculated. For categorical 158 variables, count and percentages were used. All outcome variables estimates were reported with 95% 159 confidence interval (95% CI). Wilcoxon-Mann-Whitney test was used to compare independent groups. The 160 association between categorical variables was assessed using the Fisher's test. The product-limit method 161 (Kaplan and Meier) was used to describe the time to symptom resolution. Kaplan-Meier estimator and Cox 162 proportional hazard model were used to assess the bivariate association of independent variables with the 163 time-dependent outcome. Kaplan-Meier curves were plotted to depict the association between each 164 predictor and symptom persistence and the Log-rank test was used to compare survival functions. Predictors 165 associated with the time to symptom resolution with a probability < 0.05 were considered significant. A two-166 sided test of less than 0.05 was considered statistically significant in all analyses. All statistical analyses 167 were performed with the use of Stata Version 17.0 (College Station, TX: StataCorp LP).

169 Results

The first patient was enrolled on December 9, 2021. Overall, 319 patients underwent randomisation by January 20, 2022, and were assigned to receive bamlanivimab/etesevimab (106 patients), sotrovimab (107 patients), or casirivimab/imdevimab (106 patients). No patients reported previous SARS-CoV-2 infections. No patients withdrew from the trial. VOC data were available for 311 patients: 170 (53.3%) were infected with Omicron and 141 (44.2%) with Delta. Eight (2.5%) patients were excluded from this analysis due to the lack of SARS-CoV-2 VOC identification. Baseline characteristics of the population by type of SARS-CoV-2 VOC are reported in Table 1.

177 Comparing symptoms at enrolment by VOC, anosmia/ageusia (p < 0.001), nausea/vomiting (p < 0.001), and 178 feeling feverish or hot (p < 0.01) were significantly more frequent among patients infected with Delta, while 179 sore throat (p < 0.001) was significantly more frequent among patients infected with Omicron. Serological 180 positivity to anti-SARS-CoV-2 antibodies (p < 0.001) and complete primary COVID-19 vaccination series 181 within 180 days of the enrolment or booster vaccination (p < 0.001) were significantly more frequent among 182 patients infected with Omicron. Table 2 shows the bivariate Cox regression of symptom resolution predictors 183 by type of SARS-CoV-2 VOC. No predictors were associated with the time to symptom resolution in both 184 SARS-CoV-2 VOC.

185 Delta VOC

Baseline characteristics of 141 patients infected with Delta VOC by type of treatment are reported in Table 3. The main detected lineages were 34 AY.4 (24.1%), 33 AY.43 (23.4%), and 26 AY.122 (18.4%). 77 (54.6%) were male, median age was 65.7 years (IQR±15.4), 115 (78.8%) had at least one comorbidity, 74 (52.5%) were serum antibody-positive at the enrolment, and 23 (16.3%) received complete primary COVID-19 vaccination series within 180 days of the enrolment or booster vaccination.

No disease progression was recorded. An emergency department visit without hospitalisation was observed
 once in one patient in the casirivimab/imdevimab group. This visit was not deemed to be related to COVID 193
 19.

The median time to symptom resolution was 7 days (95% Cl 7 - 13) in the bamlanivimab/etesevimab group, 10 days (95% Cl 7 - 14) in the sotrovimab group, and 10 days (95% Cl 7 - 15) in the casirivimab/imdevimab group, not differing significantly among the overall groups of treatment (Log-rank Chi-square 0.22, p 0.895) and for each comparison between treatment groups, namely bamlanivimab/etesevimab with casirivimab/imdevimab (Log-rank Chi-square 0.08, p 0.776), sotrovimab with casirivimab/imdevimab (Logrank Chi-square 0.40, p 0.527), and bamlanivimab/etesevimab with sotrovimab (Log-rank Chi-square 0.01, p

200 0.92). Figure 1 shows the survival time to symptom resolution by type of treatment in the Delta study 201 population. The Cox regression analysis confirmed the non-significantly different effects upon the time to 202 symptom resolution between casirivimab/imdevimab (reference standard according to the original trial 203 protocol) and both bamlanivimab/etesevimab and sotrovimab (HR 1.052 and HR 1.097, 95% CI 0.704 -204 1.573 and 0.729 - 1.652, *p* 0.805 and 0.657, respectively).

205 Omicron VOC

Baseline characteristics of 170 patients infected with Omicron VOC by type of treatment are reported in Table 4. The detected lineages were 137 (80.6%) BA.1 and 33 (19.4%) BA.1.1. 101 (59.4%) were male, median age was 64.5 years (IQR±14.8), 135 (79.4%) had at least one comorbidity, 134 (78.8%) were serum antibody-positive at the enrolment, and 66 (38.8%) received complete primary COVID-19 vaccination series within 180 days of the enrolment or booster vaccination.

211 Two of 53 in the bamlanivimab/etesevimab group (3.8%) had disease progression leading to hospitalisation 212 and no disease progression was recorded in the casirivimab/imdevimab and sotrovimab groups. The primary 213 reasons for the two hospitalisations were deemed to be related to COVID-19. Both patients admitted to 214 hospital were serum antibody-negative at enrolment and underwent non-invasive mechanical ventilation at 215 hospital admission. One of these patients, a man aged 71-75 who received three doses of SARS-CoV-2 216 vaccine and was affected by non-Hodgkin lymphoma under active chemotherapy and chronic heart failure, 217 died 12 days after the symptom onset, 10 days after the administration of bamlanivimab/etesevimab, and 4 218 days after the hospitalisation. The other patient, a man aged 66-70 who was not vaccinated against SARS-219 CoV-2 and was affected by obesity (body mass index, 31) and type 2 diabetes, was admitted 7 days after 220 the symptom onset and 4 days after the administration of bamlanivimab/etesevimab; the length of his 221 hospital stay was 22 days, including non-invasive mechanical ventilation for 13 days and low-flow oxygen 222 therapy for 8 days. All-cause mortality through day 28 was the same as the one through day 14.

An emergency department visit without hospitalisation was observed once in one patient in the bamlanivimab/etesevimab group. This visit was not deemed to be related to COVID-19.

The median time to symptom resolution was 12 days (95% Cl 8 - 14) in the bamlanivimab/etesevimab group, 12 days in the casirivimab/imdevimab group (95% Cl 9 - 16), and 7 days in the sotrovimab group (95% Cl 6 -9), turning out to be 5 days shorter in the sotrovimab group compared to both bamlanivimab/etesevimab and casirivimab/imdevimab groups (HR 0.526 and HR 0.451, 95% Cl 0.359 - 0.77 and 95% Cl 0.303 - 0.669, *p* 0.001 and 0.0001, respectively). Figure 2 shows the survival time to symptom resolution by type of treatment in the Omicron study population. In each of the assessed subgroups (SARS-CoV-2 serological and

- 231 vaccination status), sotrovimab showed a significantly shorter time to symptom resolution compared to
- bamlanivimab/etesevimab and casirivimab/imdevimab, as reported in Table 5.

233 Discussion

234 During the SARS-CoV-2 pandemic, the paradigm of discovering and implementing mAb and antiviral 235 treatments based on the randomised controlled trials has lagged significantly behind the new evidence 236 coming from in-vitro studies, which has driven clinical recommendations causing ethical dilemmas on the 237 continuation of ongoing trials. At the time of approving the MANTICO trial protocol (November 2021), 238 casirivimab/imdevimab, bamlanivimab/etesevimab, and, later, sotrovimab were the only therapies 239 recommended by the COVID-19 treatment guidelines for outpatients with mild to moderate COVID-19 at high 240 risk of progressing to severe disease. Delta was the SARS-CoV-2 dominant VOC worldwide and the 241 selection of the study mAbs was based on their in-vitro activity against the circulating variants and on the 242 existing evidence of their clinical efficacy. After mid-December 2021, the Omicron VOC has been spreading 243 worldwide, rapidly becoming the dominant VOC. Preliminary in-vitro studies on Omicron demonstrated 244 numerous mutations in the gene encoding the spike protein, predicting a markedly reduced susceptibility to 245 bamlanivimab/etesevimab and casirivimab/imdevimab [3-5]. According to these findings, FDA and AIFA 246 have revised the emergency use authorization for bamlanivimab/etesevimab and casirivimab/imdevimab, 247 halting their use, in line with the National Institutes of Health (NIH) COVID-19 Treatment Guidelines Panel, 248 which advised against the use of these mAbs due to reduced activity against Omicron and because real-time 249 testing to identify rare, non-Omicron variants is not readily available [15]. Therefore, the study enrolment in a 250 real-life outpatient setting was prematurely discontinued for possible futility, after the inclusion of barely one 251 fourth of the predefined sample size. Nevertheless, the recruitment timeframe provided a unique opportunity 252 to collect data on the clinical efficacy of bamlanivimab/etesevimab, casirivimab/imdevimab, and sotrovimab 253 in patients infected with Omicron.

Overall, the three treatment groups appeared to be balanced with respect to the predictors of outcomes in both Delta and Omicron population, as expected under the randomised allocation design. As reported by previous studies, patients infected with Omicron were more likely than those infected with Delta to present with symptoms limited to the upper respiratory tract and to have pre-existing immunity, considering that Omicron is better equipped than Delta to infect people with pre-existing immunity [16].

259 Considering the time to symptom resolution, no differences in the effect between treatment groups was 260 found in Delta infections, whereas sotrovimab showed a significant benefit compared to 261 bamlanivimab/etesevimab and casirivimab/imdevimab in patients infected with Omicron BA.1 and BA.1.1. 262 This benefit was consistent across all Omicron subgroups, regardless of the SARS-CoV-2 serology and

263 vaccination status, confirming the preliminary in-vitro evidence on the mAbs activity against Omicron BA.1

264 and BA.1.1 [3-5].

265 The disease progression was recorded in two patients infected with Omicron, who were both randomised to 266 receive bamlanivimab/etesevimab. The absence of COVID-19 progression in two treatment groups 267 (casirivimab/imdevimab and sotrovimab) in the Omicron study population, as well as in all three treatment 268 groups in the Delta study population, could be influenced by the small sample size, the lower intrinsic-269 severity of Omicron, the high vaccination rate in Italy, and the prioritization of the booster vaccination for the 270 elderly [17]. Nevertheless, these findings are consistent with recent in-vitro data showing that all study 271 treatments were active against Delta and both casirivimab/imdevimab and sotrovimab retained a residual 272 neutralizing activity against Omicron, whereas bamlanivimab/etesevimab did not neutralize Omicron [18-20]. 273 Additional clinical studies with an adequate sample size are required to determine whether 274 casirivimab/imdevimab and sotrovimab are indeed effective in preventing COVID-19 progression due to 275 Omicron infection. Should the role of casirivimab/imdevimab in preventing severe COVID-19 due to Omicron 276 infections be confirmed, this mAb could represent a readily-available and well-tolerated treatment option in 277 case of shortages of mAbs supplies and contraindication to other early COVID-19 treatments. 278 The MANTICO trial provides the first data on the clinical efficacy of bamlanivimab/etesevimab,

278 The MANTICO that provides the first data on the clinical efficacy of barnanivimab/etesevimab, 279 casirivimab/imdevimab, and sotrovimab against Omicron VOC. There is an urgent need for adaptive clinical 280 trials comparing anti-SARS-CoV-2 treatments by VOC to promptly inform recommendations for the 281 management of early COVID-19.

282 Competing interests

- Lolita Sasset has served as a paid consultant to Abbvie, Janssen, MSD, Gilead Sciences, Janssen, MSD
- and ViiV Healthcare; she does not have any financial competing interests with this study. Annamaria
- 285 Cattelan has served as a paid consultant to Abbvie, Janssen, MSD, and received research fundings from
- 286 Gilead Sciences, Janssen, MSD and ViiV Healthcare; she does not have any financial competing interests
- with this study. Carlo Tascini has received grants from Correvio, Biotest, Biomerieux, Gilead, Angelini, MSD,
- 288 Pfizer, Thermofisher, Zambon, Shionogi, Avir Pharma and Hikma outside the submitted work in the last two
- 289 years. The other authors do not have any financial and non-financial competing interests.

290 References291

- Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ, 2020; 369: m1966. DOI: 10.1136/bmj.m1966
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020; 395: 497-506. DOI: 10.1016/S0140-6736(20)30183-5
- Cao, Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature, 2022; 602: 657–663. DOI: 10.1038/s41586-021-04385-3
- Planas, D., Saunders, N., Maes, P. *et al.* Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature, 2022; 602: 671–675. DOI: 10.1038/s41586-021-04389-z
- 5. Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell, 2022; 185: 447-456. DOI: 10.1016/j.cell.2021.12.046
- Andrews N, Stowe J, Kirsebom F, et al. (2022) Covid-19 vaccine effectiveness against the Omicron (B.
 1.1. 529) variant. N Engl J Med [in press]. DOI: 10.1056/NEJMoa2119451
- Benton DJ, Wrobel AG, Xu P, et al. Receptor binding and priming of the spike protein of SARS-CoV-2
 for membrane fusion. Nature, 2020; 588: 327-330. DOI: 10.1038/s41586-020-2772-0
- Bougan M, Nirula A, Azizad M, et al. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. N
 Engl J Med, 2021; 385: 1382-1392. DOI: 10.1056/NEJMoa2102685
- Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV Antibody Combination and Outcomes
 in Outpatients with Covid-19. N Engl J Med, 2021; 385: e81. DOI: 10.1056/NEJMoa2108163ù
- 311
 10. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. COMET-ICE Investigators. Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med, 2021; 385: 1941-1950. DOI: 10.1056/NEJMoa2107934
- 11. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines:
 clinical spectrum of SARS-CoV-2 infection. National Institutes of Health. Available
 at https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/. Accessed 17 April 2022.
- U.S. Department of Health and Human Services Food and Drug Administration. Assessing COVID19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment. Available at <u>https://www.fda.gov/regulatory-</u> information/search-fda-guidance-documents/assessing-covid-19-related-symptoms-outpatient-adultand-adolescent-subjects-clinical-trials-drugs. Accessed 30 March 2022.
- Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture
 (REDCap): a metadata-driven methodology and workflow process for providing translational research
 informatics support. J Biomed Inform, 2009; 42: 377-381. DOI: 10.1016/j.jbi.2008.08.010
- 14. U.S. Department of Health and Human Services Food and Drug Administration. COVID-19: developing drugs and biological products for treatment or prevention. Available at <u>https://www.fda.gov/regulatory-</u> information/search-fda-guidance-documents/covid-19-developing-drugs-and-biological-productstreatment-or-prevention. Accessed 30 March 2022.
- 15. National Institutes of Health. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019
 (COVID-19) Treatment Guidelines. Available at <u>https://www.covid19treatmentguidelines.nih.gov/</u>.
 Accessed 13 Feb 2022.
- Nyberg T, Ferguson NM, Nash SG, et al. (2022) Comparative analysis of the risks of hospitalisation and
 death associated with SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants in England: a
 cohort study. Lancet [in press]. DOI: 10.1016/S0140-6736(22)00462-7
- Bhattacharyya RP and Hanage, WP. Challenges in Inferring Intrinsic Severity of the SARS-CoV-2
 Omicron Variant. N Engl J Med, 2022; 386: e14. DOI: 10.1056/NEJMp2119682
- Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of Antibodies and Antiviral Drugs against Covid Omicron Variant. N Engl J Med, 2022; 386: 995-998. DOI: 10.1056/NEJMc2119407
- 19. Iketani, S., Liu, L., Guo, Y, et al. (2022) Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature [in press]. DOI: 10.1038/s41586-022-04594-4
- Takashita E, Kinoshita N, Yamayoshi S, et al. (2022) Efficacy of Antiviral Agents against the SARS-CoV Omicron Subvariant BA.2. N Engl J Med [in press]. DOI: 10.1056/NEJMc2201933

343 Table 1 - Baseline characteristics of the overall study population by type of Variant of Concern

Characteristic	Delta N = 141	Omicron N = 170	<i>p</i> value
Sex (male) – n (%)	77 (54.61)	101 (59.41)	0.421
Age – median (interquartile range) [range]	65.7 (15.4) [50-92]	64.5 (14.8) [50-90]	0.585
Smoking status – n (%)	· · · · · · · · · · · ·	· · · · · ·	
Smoker	8 (5.67)	24 (14.12)	0.015
Former smoker	32 (22.70)	28 (16.47)	0.194
Non smoker	101 (71.63)	118 (69.41)	0.709
Body Mass Index – n (%)		· ·	
≤29	100 (70.92)	132 (77.65)	0.192
≥30	41 (29.08)	38 (22.35)	0.192
SARS-CoV-2 serological status – n (%)			
Antibody-positive	74 (52.48)	134 (78.82)	<0.001
Antibody-negative	64 (45.39)	35 (20.59)	<0.001
Other	3 (2.13)	1 (0.59)	
Anti-SARS-CoV-2 vaccination status – n (%)			
3 doses or 2 doses ≤ 120 days	23 (16.31)	66 (38.82)	<0.001
1 or 2 doses ≥ 120 days or not vaccinated	113 (80.14)	99 (58.24)	<0.001
Other	5 (3.55)	5 (2.94)	
Comorbidities – n (%)			
Diabetes	3 (2.13)	6 (3.53)	0.519
Cardiovascular disease	57 (40.43)	61 (35.88)	0.414
Chronic kidney disease	7 (4.96)	9 (5.29)	1.000
Chronic liver disease	4 (2.84)	12 (7.06)	0.061
Chronic pulmonary disease	19 (13.48)	33 (19.41)	0.173
Immunocompromising conditions	22 (15.60)	39 (22.94)	0.116
Symptoms at enrolment – n (%)			
Cough	99 (70.21)	118 (69.41)	0.902
Nasal congestion	70 (49.65)	69 (40.59)	0.136
Sore throat	33 (23.40)	69 (40.59)	<0.001
Feeling hot or feverish	103 (73.05)	99 (58.24)	0.009
Myalgia	47 (33.33)	54 (31.76)	0.808
Fatigue	49 (34.75)	75 (44.12)	0.104
Headache	60 (42.55)	60 (35.29)	0.200
Anosmia/ageusia	41 (29.08)	4 (2.35)	<0.001
Nausea/vomiting	28 (19.86)	11 (6.47)	<0.001
Diarrhoea	15 (10.64)	12 (7.06)	0.314
Serum C-reactive protein level – n	140	161	
Mean (standard deviation)	20.26 (28.66)	14.29 (21.72)	0.026

345	Table 2 – Bivariate Cox regression of symptom resolution predictors by type of Variant of Concern
346	

	Delta		Omicron	
Predictor	Hazard ratio (95% CI)	p value	Hazard ratio (95% CI)	<i>p</i> value
Gender	0.796 (0.569 - 1.113)	0.182	0.836 (0.613 - 1.139)	0.257
Age	1.0005 (0.984 - 1.017)	0.952	0.996 (0.980 - 1.012)	0.626
Body Mass Index	1.035 (0.716 - 1.495)	0.855	1.171 (0.815 - 1.684)	0.393
SARS-CoV-2 serological status	0.934 (0.667 - 1.307)	0.690	0.823 (0.566 - 1.196)	0.307
Anti-SARS-CoV-2 vaccination status	1.299 (0.827 - 2.040)	0.257	0.906 (0.662 - 1.24)	0.539
Diabetes	0.633 (0.34 - 1.179)	0.150	1.19 (0.758 - 1.879)	0.444
Cardiovascular disease	0.964 (0.686 - 1.354)	0.831	0.852 (0.621 - 1.168)	0.319
Chronic kidney disease	1.24 (0.577 - 2.665)	0.581	1.125 (0.573 - 2.209)	0.733
Chronic liver disease	2.417 (0.761 - 7.683)	0.135	1.33 (0.738 - 2.401)	0.341
Chronic pulmonary disease	0.778 (0.461 - 1.313)	0.346	0.976 (0.666 - 1.431)	0.902
Immunocompromising conditions	0.997 (0.597 - 1.664)	0.989	0.802 (0.55 - 1.169)	0.252

348 349

Table 3 - Baseline characteristics of the study population infected with Delta by type of treatment

Characteristic	Total N = 141	Sotrovimab N = 44	Bamlanivimab/ Etesevimab N = 47	Casirivimab/ Imdevimab N = 50		
Sex (male) – n (%)	77 (54.61)	23 (52.27)	25 (53.19)	29 (58.00)		
Age – median (interguartile range) [range]	65.7 (15.4) [50-92]	65.8 (16.4) [50-90]	68.6 (11.8) [50-92]	63.2 (12) [50-89]		
Smoking status – n ($\%$)						
Smoker	8 (5.67)	2 (4.45)	4 (8.51)	2 (4.00)		
Former smoker	32 (22.70)	8 (18.18)	11 (23.40)	13 (26.00)		
Non smoker	101 (71.63)	34 (77.27)	32 (68.09)	35 (70.00)		
Body Mass Index – n (%)	4 · · ·					
≤29	100 (70.92)	29 (65.91)	35 (74.47)	36 (72.00)		
≥30	41 (29.08)	15 (34.09)	12 (25.53)	14 (28.00)		
SARS-CoV-2 serological status – n (%)	* · ·					
Antibody-positive	74 (52.48)	22 (50.00)	30 (63.83)	22 (44.00)		
Antibody-negative	64 (45.39)	22 (50.00)	16 (34.04)	26 (52.00)		
Other	3 (2.13)	0	1 (2.13)	2 (4.00)		
Anti-SARS-CoV-2 vaccination status – n (%)			•			
3 doses	16 (11.35)	6 (13.64)	3 (6.38)	7 (14.00)		
2 doses ≤ 120 days	7 (4.96)	2 (4.55)	2 (4.26)	3 (6.00)		
1 or 2 doses ≥ 120 days	55 (39.01)	16 (36.36)	24 (51.06)	15 (30.00)		
Not vaccinated	58 (41.13)	18 (40.91)	16 (34.04)	24 (48.00)		
Other	5 (3.55)	2 (4.55)	2 (4.26)	1 (2.00)		
Comorbidities – n (%)						
Diabetes	3 (2.13)	0	2 (4.26)	1 (2.00)		
Cardiovascular disease	57 (40.43)	18 (40.91)	20 (42.55)	19 (38.00)		
Chronic kidney disease	7 (4.96)	1 (2.27)	2 (4.26)	4 (8.00)		
Chronic liver disease	4 (2.84)	1 (2.27)	1 (2.13)	2 (4.00)		
Chronic pulmonary disease	19 (13.48)	7 (15.91)	5 (10.64)	7 (14.00)		
Immunocompromising conditions	22 (15.60)	6 (13.64)	7 (14.89)	9 (18.00)		
Symptoms at enrolment – n (%)						
Cough	99 (70.21)	30 (68.18)	36 (76.60)	33 (66.00)		
Nasal congestion	70 (49.65)	20 (45.45)	22 (46.81)	28 (56.00)		
Sore throat	33 (23.40)	11 (25.00)	8 (17.02)	14 (28.00)		
Feeling hot or feverish	103 (73.05)	31 (70.45)	36 (76.60)	36 (72.00)		
Myalgia	47 (33.33)	11 (25.00)	16 (34.04)	20 (40.00)		
Fatigue	49 (34.75)	14 (31.82)	15 (31.91)	20 (40.00)		
Headache	60 (42.55)	15 (34.09)	15 (31.91)	30 (60.00)		
Anosmia/ageusia	41 (29.08)	13 (29.55)	15 (31.91)	13 (26.00)		
Nausea/vomiting	28 (19.86)	6 (13.64)	9 (19.15)	13 (26.00)		
Diarrhoea	15 (10.64)	1 (2.27)	5 (10.64)	9 (18.00)		
Serum C-reactive protein level – n	140	43	46	51		
Mean (standard deviation)	20.26 (28.66)	22.15 (33.04)	25.27 (34.20)	14.14 (15.78)		

351 Table 4 – Baseline characteristics of the study population infected with Omicron by type of treatment

Characteristic	Total N = 170	Sotrovimab N = 61	Bamlanivimab/ Etesevimab N = 57	Casirivimab/ Imdevimab N = 52
Sex (male) – n (%)	101 (59.41)	36 (59.02)	30 (52.63)	35 (67.31)
Age – median (interquartile range) [range]	64.5 (14.8) [50-90]	64.2 (15) [50-90]	64.8 (14.6) [50-86]	65.3 (14.8) [50-86]
Smoking status – n (%)				
Smoker	24 (14.12)	6 (9.84)	11 (19.30)	7 (13.46)
Former smoker	28 (16.47)	9 (14.75)	11 (19.30)	8 (15.38)
Non smoker	118 (69.41)	46 (75.41)	35 (61.40)	37 (71.15)
Body Mass Index – n (%)	·			
≤29	132 (77.65)	53 (86.89)	42 (73.68)	37 (71.15)
≥30	38 (22.35)	8 (13.11)	15 (26.32)	15 (28.85)
SARS-CoV-2 serological status – n (%)				
Antibody-positive	134 (78.82)	45 (73.77)	45 (78.95)	44 (84.62)
Antibody-negative	35 (20.59)	16 (26.23)	11 (19.30)	8 (15.38)
Other	1 (0.59)	0	1 (1.75)	0
Anti-SARS-CoV-2 vaccination status – n (%)				
3 doses	62 (36.47)	24 (39.34)	19 (33.33)	19 (36.54)
2 doses ≤ 120 days	4 (2.35)	2 (3.28)	1 (1.75)	1 (1.92)
1 or 2 doses ≥ 120 days	57 (33.53)	16 (26.23)	22 (38.60)	19 (36.54)
Not vaccinated	42 (24.71)	18 (29.51)	13 (22.81)	11 (21.15)
Other	5 (2.94)	1 (1.64)	2 (3.51)	2 (3.85)
Comorbidities – n (%)				
Diabetes	6 (3.53)	2 (3.28)	2 (3.51)	2 (3.85)
Cardiovascular disease	61 (35.88)	18 (29.51)	17 (29.82)	26 (50.00)
Chronic kidney disease	9 (5.29)	4 (6.56)	2 (3.51)	3 (5.77)
Chronic liver disease	12 (7.06)	4 (6.56)	5 (8.77)	3 (5.77)
Chronic pulmonary disease	33 (19.41)	11 (18.03)	15 (26.32)	7 (13.46)
Immunocompromising conditions	39 (22.94)	17 (27.87)	11 (19.30)	11 (21.15)
Symptoms at enrolment – n (%)				
Cough	118 (69.41)	42 (68.85)	37 (64.91)	39 (75.00)
Nasal congestion	69 (40.59)	28 (45.90)	25 (43.86)	16 (30.77)
Sore throat	69 (40.59)	22 (36.07)	27 (47.37)	20 (38.46)
Feeling hot or feverish	99 (58.28)	37 (60.66)	32 (56.14)	30 (57.69)
Myalgia	54 (31.76)	20 (32.79)	18 (31.58)	16 (30.77)
Fatigue	75 (44.12)	31 (50.82)	20 (35.09)	24 (46.15)
Headache	60 (35.29)	23 (37.70)	20 (35.09)	17 (32.69)
Anosmia/ageusia	4 (2.35)	1 (1.64)	2 (3.51)	1 (1.92)
Nausea/vomiting	11 (6.47)	4 (6.56)	5 (8.77)	2 (3.85)
Diarrhoea	12 (7.06)	5 (8.20)	4 (7.02)	3 (5.77)
Serum C-reactive protein level – n	161	57	56	48
Mean (standard deviation)	14.29 (21.72)	12.65 (15.97)	17.19 (31.07)	12.87 (12.55)

353 Table 5 - Cox regression to assess the difference between treatment effects upon the time to

354 symptom resolution in selected subgroups of interest in the study population infected with Omicron

Subgroup	Sotrovimab	Bamlanivimab/etesevimab		Casirivimab/imdevimab		
Subgroup	Hazard ratio	Hazard ratio (95% CI)	p value	Hazard ratio (95% CI)	<i>p</i> value	
SARS-CoV-2 serological status						
Antibody-negative	1	0.345 (0.158 - 0.753)	0.008	0.415 (0.177 -0.973)	0.043	
Antibody-positive	1	0.398 (0.221 - 0.714)	0.002	0.318 (0.175 - 0.575)	<0.001	
Anti-SARS-CoV-2 vaccination status						
1 or 2 doses ≥ 120 days	1	0 472 (0 280 0 772)	0.002	0.405 (0.208 0.821)	0.006	
or not vaccinated	I	0.472 (0.289 - 0.772)	0.003	0.495 (0.298 - 0.821)	0.000	
3 doses	1	0 504 (0 284 - 0 894)	0.010	0.346 (0.194 - 0.62)	~0.001	
or 2 doses ≤ 120 days	I	0.304 (0.284 - 0.894)	0.019	0.040 (0.194 - 0.02)	NO.001	

356 Figure 1 - Survival time to symptom resolution by type of treatment in the study population infected

357 with Delta



364 Figure 2 - Survival time to symptom resolution by type of treatment in the study population infected

365 with Omicron

